A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
Status:
Completed
Trial end date:
2020-07-20
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and potential effects on cognition of
GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects
with Parkinson's disease and cognitive impairment.
Phase:
Phase 2
Details
Lead Sponsor:
Alkahest, Inc.
Collaborator:
Michael J. Fox Foundation for Parkinson's Research